Tesaro Using Myriad HRD Test in Investigational PARP Inhibitor Studies | GenomeWeb

NEW YORK (GenomeWeb News) – Tesaro will use Myriad Genetics' Homologous Recombination Deficiency (HRD) test to identify best responders to its investigational PARP inhibitor, niraparib, Myriad said today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.